AAPDNRETF
AAPDNRETF is a dominant minor histocompatibility antigen presented by H-2Db， which antigen is expressed in C57BL/6 mice and can be recognized by T cells from C3H.SW mice, thereby inducing a strong immune response. AAPDNRETF can induce graft-versus-host disease in irradiated C57BL/6 recipient mice via transfer of sensitized T lymphocytes. AAPDNRETF is applicable to the research of graft-versus-host disease.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 179953-98-1
- Formule: C43H65N13O16
- Masse moléculaire:1020.05
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
AAPDNRETF (0.01 nM-1 μM) effectively sensitizes target cells expressing H-2Db(e.g., T2Db cells) at an extremely low concentration (10 pM), rendering them susceptible to killing by mouse effector T cells (CTL)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
AAPDNRETF (300 µg/mouse; s.c.; administered twice at 7-day intervals) induces T lymphocytes that cause severe non-lethal graft-versus-host disease and thymic hypoplasia in irradiated male C57BL/6J recipient mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C3H.SW/SnJ (male, 8-20 wk old)[1]
-
Dosage:50 µg; 100 µg; 300 µg
-
Administration:s.c.; administered twice at 7-day intervals
-
Result:Generated potent CTL responses that killed both unmanipulated C57BL/6 target cells and C3H.SW target cells coated with synthetic AAPDNRETF peptide.
Induced CTL activity comparable to that induced by priming with C57BL/6 cells.
-
Animal Model:C3H.SW/SnJ (male, 8-20 wk old, donor); C57BL/6J (male, 8-20 wk old, recipient, irradiated 950 rads)[1]
-
Dosage:300 µg (donor priming)
-
Administration:s.c.; administered twice at 7-day intervals (donor priming)
-
Result:Caused 6/7 recipient mice to develop cutaneous GVHD (hair loss, erythematous lesions, skin ulcerations) starting around day 25, with lesions worsening up to day 60.
Induced significant thymic hypoplasia, with a 50% reduction in total Thy1.2+ thymocytes, CD4+CD8+ double positive thymocytes, CD4+TCRαβ high single positive thymocytes, and CD8+TCRαβ high single positive thymocytes compared to control recipients by day 60.
Maintained 100% recipient survival through day 60.
Chemical Information
-
CAS No. 179953-98-1
-
Masse moléculaire 1020.05
-
Formule C43H65N13O16
-
Sequence
Ala-Ala-Pro-Asp-Asn-Arg-Glu-Thr-Phe
-
Sequence Shortening
AAPDNRETF
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
AAPDNRETF Related Classifications
HY-P11699 Related Classifications
Powered by Bioz